QT Sense, a Groningen-based startup, has secured €6 million ($6.3M USD) in funding to advance its quantum sensing technology for disease diagnostics at the single-cell level. The funding includes equity investment from QDNL Participations, a quantum-focused VC fund, and grants from Interreg Europe. The company’s flagship product, Quantum Nuova, is a single-cell Nano-MRI platform designed to measure cellular activity with high precision, enabling early sepsis diagnostics and personalized cancer treatment.
Founded in February 2024 as a spinout from the University Medical Center Groningen (UMCG), QT Sense leverages nanodiamond-based quantum sensing to detect changes in cellular activity. The technology involves exposing nanodiamonds to individual cells and measuring changes in light emission, which correspond to cellular processes. This approach provides real-time, single-cell resolution insights into oxidative stress and other biomarkers, offering significant advantages over traditional diagnostic methods.
The new funding will support the refinement of Quantum Nuova, with the first version set to be deployed at UMCG for sepsis diagnostics research. QT Sense’s technology has potential applications in drug development, personalized medicine, and academic research. The company’s team, led by Dr. Deepak Veeregowda (CEO) and Prof. Dr. Romana Schirhagl (CSO), combines expertise in quantum sensing, life sciences, and product development, positioning QT Sense to bridge the gap between laboratory research and practical healthcare solutions.
For more details, visit the original article by EU-Startups here.
February 26, 2025
